We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+38.9%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.13B
AUM Growth
+$1.33B
Cap. Flow
+$252M
Cap. Flow %
3.09%
Top 10 Hldgs %
38.33%
Holding
153
New
32
Increased
35
Reduced
44
Closed
13

Top Buys

Rank Stock Value
1
AGN
Allergan Inc
AGN
+$182M
2
ISRG icon
Intuitive Surgical
ISRG
+$111M
3
ESRX
Express Scripts Holding Company
ESRX
+$60.7M
4
ABBV icon
AbbVie
ABBV
+$52.2M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$48.2M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$78.6M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$61.6M
3
CELG
Celgene Corp
CELG
+$61.1M
4
INCY icon
Incyte
INCY
+$58.6M
5
UNH icon
UnitedHealth
UNH
+$51.9M

Sector Composition

Rank Sector Weight
1 Healthcare 83.16%
2 Technology 0.09%
3 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICPT
1
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$572M 7.04%
1,734,934
– –
GILD icon
2
Gilead Sciences
GILD
$167B
$377M 4.63%
5,314,800
+322,200
+6% +$25.3M
BIIB icon
3
Biogen
BIIB
$30.4B
$324M 3.99%
1,060,700
-34,400
-3% -$10.9M
BMY icon
4
Bristol-Myers Squibb
BMY
$130B
$310M 3.81%
5,966,400
+501,400
+9% +$26.7M
RLYP
5
DELISTED
RELYPSA INC COM
RLYP
$296M 3.64%
9,941,551
+2
+0% +$72
AMGN icon
6
Amgen
AMGN
$212B
$286M 3.51%
2,315,900
-199,400
-8% -$24.2M
AGN
7
DELISTED
Allergan Inc
AGN
$282M 3.46%
2,270,000
+1,494,800
+193% +$182M
ABBV icon
8
AbbVie
ABBV
$465B
$246M 3.03%
4,793,800
+1,032,900
+27% +$52.2M
HCA icon
9
HCA Healthcare
HCA
$92.8B
$221M 2.72%
4,215,000
+457,000
+12% +$22.7M
ILMN icon
10
Illumina
ILMN
$29.2B
$202M 2.49%
1,398,594
-242,916
-15% -$35.7M
ITMN
11
DELISTED
INTERMUNE INC
ITMN
$199M 2.45%
5,952,000
-1,745,000
-23% -$38.9M
CELG
12
DELISTED
Celgene Corp
CELG
$191M 2.35%
2,742,800
-771,400
-22% -$61.1M
VTRS icon
13
Viatris
VTRS
$20.8B
$191M 2.35%
3,905,500
-309,000
-7% -$15M
MDVN
14
DELISTED
MEDIVATION, INC.
MDVN
$175M 2.16%
5,448,200
-798,800
-13% -$29.5M
A icon
15
Agilent Technologies
A
$39.7B
$170M 2.09%
4,253,555
+34,950
+0.8% +$1.44M
TMO icon
16
Thermo Fisher Scientific
TMO
$214B
$168M 2.06%
1,393,200
-141,000
-9% -$16.8M
INCY icon
17
Incyte
INCY
$26B
$167M 2.06%
3,124,000
-945,000
-23% -$58.6M
PRGO icon
18
Perrigo
PRGO
$1.43B
$163M 2.01%
1,056,800
+283,800
+37% +$44.8M
REGN icon
19
Regeneron Pharmaceuticals
REGN
$72.9B
$162M 1.99%
539,000
-199,800
-27% -$61.6M
ESRX
20
DELISTED
Express Scripts Holding Company
ESRX
$157M 1.94%
2,097,000
+810,000
+63% +$60.7M
ISRG icon
21
Intuitive Surgical
ISRG
$130B
$147M 1.81%
3,026,700
+2,356,200
+351% +$111M
MRK icon
22
Merck
MRK
$326B
$145M 1.78%
2,669,256
– –
IPXL
23
DELISTED
Impax Laboratories, Inc.
IPXL
$141M 1.74%
5,345,600
+1,108,000
+26% +$27.7M
PFE icon
24
Pfizer
PFE
$144B
$118M 1.45%
3,858,694
+113,832
+3% +$3.39M
MCK icon
25
McKesson
MCK
$104B
$102M 1.26%
579,000
+224,000
+63% +$39.1M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2014 Portfolio in Review

As of Q1 2014, OrbiMed held 153 positions worth $8.13B, up 20% from $6.8B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed deployed $252M of net new capital in Q1 2014, opening 32 new positions and adding to 35 existing holdings. Its largest new stake was Eli Lilly: 543,000 shares worth $32M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 84% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Aetna Inc, an estimated $78.6M trimmed.

  • OrbiMed's largest Q1 2014 buy was Eli Lilly: 543,000 shares worth $32M.
  • OrbiMed added most to Allergan Inc in Q1 2014, an estimated $182M increase.
  • OrbiMed's biggest Q1 2014 reduction was Aetna Inc, cutting an estimated $78.6M.
  • OrbiMed fully exited QIAGEN NV in Q1 2014, selling an estimated $45.9M.
  • OrbiMed's ten largest holdings make up 38% of its $8.13B portfolio in Q1 2014.
  • OrbiMed opened 32 new positions and closed 13 in Q1 2014.
  • OrbiMed's portfolio value rose 20% quarter-over-quarter to $8.13B.

Based on OrbiMed's 13F filing for Q1 2014, filed 15 May 2014.